| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive system disease; Endocrine system disease; Reproductive system disease | Under Review | Rat, Mouse, Human | 0.4 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous system disease | Under Development | Rat | 0.11 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive system disease | Under Review | Human, Rat, Mouse | 0.12 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | Pimephales promelas | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Medaka, Zebrafish | 0.25 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| KE:288 | Activation of specific nuclear receptors, Transcriptional change | ||||||
| AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory system disease | Under Development | Human, Mouse | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary system disease | WPHA/WNT Endorsed | Mouse, Human | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
| KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | ||||||
| KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | ||||||
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.29 | KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| AOP:73 | Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity | Unclassified | - | 0.08 | KE:528 | Decreased, Synthesis of NE | |
| AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:96 | Axonal sodium channel modulation leading to acute mortality | Unclassified | - | Insects, Fish | 0.17 | KE:602 | Increased, Ataxia, paralysis, or hyperactivity |
| AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | Zebrafish | 0.29 | KE:635 | Decreased, locomotion |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:104 | Altered ion channel activity leading impaired heart function | Unclassified | - | 0.25 | KE:698 | Altered, Action Potential | |
| AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.17 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
| AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory system disease | - | Mus musculus | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
| AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.29 | KE:281 | Thyroxine (T4) in serum, Decreased |
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.17 | KE:111 | Agonism, Estrogen receptor |
| AOP:113 | Glutamate-gated chloride channel activation leading to acute mortality | Unclassified | - | Bombus impatiens, Chaetanaphothrips orchidii, Radopholus similis, Daphnia magna, Orius insidiosus, Hymenoptera, Helicoverpa zea, Lepidoptera, Liriomyza trifolii, Orius isidiosus, Acyrthosiphon kondoi | 0.17 | KE:764 | N/A, Ataxia, paralysis, or hyperactivity |
| AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | Rattus norvegicus | 0.17 | KE:778 | Increase, Regenerative cell proliferation (corneal cells) |
| AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | Mus musculus, Rattus norvegicus | 0.2 | KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) |
| AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
| AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.29 | KE:281 | Thyroxine (T4) in serum, Decreased |
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:120 | Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus, Mus musculus | 0.2 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary system disease | - | Mus musculus, Rattus norvegicus | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | Pimephales promelas | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | Pimephales promelas | 0.18 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:126 | Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation | Unclassified | - | 0.08 | KE:848 | Decreased, Binding of NE to NE receptors on GnRH neurons | |
| AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary system disease | Under Development | Sprague-Dawley, Homo sapiens | 0.09 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign neoplasm; Respiratory system disease | Under Review | 0.29 | KE:768 | Increase, Cytotoxicity | |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:155 | Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Zebrafish | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:156 | Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:157 | Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:158 | Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.25 | KE:1003 | Decreased, Triiodothyronine (T3) |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive system disease | - | CD-1 mouse, SD rat | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
| AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.4 | KE:425 | Decrease of Thyroidal iodide |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.4 | KE:425 | Decrease of Thyroidal iodide |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:189 | Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:1116 | Decreased, Triiodothyronine (T3) in tissues |
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.33 | KE:1828 | Increased, Thyroxine (T4) in serum |
| KE:1116 | Decreased, Triiodothyronine (T3) in tissues | ||||||
| AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:1154 | Increased, Triiodothyronine (T3) in tissues |
| AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:194 | Hepatic nuclear receptor activation leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.17 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive system disease | - | Caenorhabditis elegans | 0.38 | KE:1115 | Increase, Reactive oxygen species |
| KE:1281 | Increased, DNA Damage-Repair | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal system disease | - | 0.12 | KE:1287 | Glutathione synthesis | |
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.17 | KE:1262 | Apoptosis |
| AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:218 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity | Unclassified | - | Japanese quail, Cynops pyrrhogaster | 0.33 | KE:1141 | Decreased, Reproductive Success |
| KE:1389 | Locomotor activity, decreased | ||||||
| AOP:219 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior | Unclassified | - | Japanese quail, Cynops pyrrhogaster | 0.17 | KE:1141 | Decreased, Reproductive Success |
| AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | Fish | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.14 | KE:870 | Increase, Cell Proliferation |
| AOP:274 | Histone deacetylase inhibition leads to impeded craniofacial development | Musculoskeletal system disease | - | 0.25 | KE:1558 | Collagen production, reduced | |
| AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural tube defect | - | 0.2 | KE:1560 | Altered differentiation | |
| AOP:289 | Inhibition of 5α-reductase leading to impaired fecundity in female fish | Unclassified | Under Development | Fish | 0.17 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | Mammals | 0.29 | KE:870 | Increase, Cell Proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | Zebrafish | 0.17 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | Daphnia magna, Fish | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.09 | KE:10042 | Abnormal development | |
| AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary system disease | - | Rat | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Oreochromis niloticus, Chinook salmon, Fathead minnow, European sea bass | 0.2 | KE:1789 | Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
| AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | Zebrafish | 0.25 | KE:1003 | Decreased, Triiodothyronine (T3) |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.25 | KE:1003 | Decreased, Triiodothyronine (T3) | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.25 | KE:1003 | Decreased, Triiodothyronine (T3) | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:366 | Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis | Unclassified | - | 0.29 | KE:959 | Increased, Free serum thyroxine (T4) | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:367 | Competitive binding to thyroid hormone carrier protein thyroid binding globulin (TBG) leading to altered amphibian metamorphosis | Unclassified | - | 0.29 | KE:959 | Increased, Free serum thyroxine (T4) | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:368 | Cytochrome oxidase inhibition leading to increased nasal lesions | Unclassified | - | Rodents, Human | 0.33 | KE:1825 | Increase, Cell death |
| AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine system disease; Reproductive system disease; Cancer | - | 0.2 | KE:1616 | Malformation, cryptorchidism - maldescended testis | |
| AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous system disease | Under Development | Human | 0.25 | KE:352 | N/A, Neurodegeneration |
| AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular system disease | Under Development | Homo sapiens | 0.14 | KE:1869 | Diminished protective oxidative stress response |
| AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive system disease | - | Lemna minor, Chlamydomonas reinhardtii | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive system disease | - | Lemna minor | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:388 | Deposition of ionising energy leading to population decline via programmed cell death | Reproductive system disease | - | Lemna minor | 0.2 | KE:1864 | Increase, Programmed cell death |
| AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | Zebrafish | 0.12 | KE:1821 | Decrease, Cell proliferation |
| AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.25 | KE:870 | Increase, Cell Proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:410 | GSK3beta inactivation leading to increased mortality via defects in developing inner ear | Unclassified | - | Zebrafish | 0.1 | KE:1825 | Increase, Cell death |
| AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | Fish, Mice | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory system disease | - | 0.4 | KE:1825 | Increase, Cell death | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | 0.25 | KE:1262 | Apoptosis | |
| AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.25 | KE:870 | Increase, Cell Proliferation | |
| AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic system disease; Cancer | - | Homo sapiens, Mus musculus | 0.09 | KE:870 | Increase, Cell Proliferation |
| AOP:437 | Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity | Urinary system disease | Under Development | 0.2 | KE:1392 | Oxidative Stress | |
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.22 | KE:1971 | Increased, tumor growth |
| KE:1262 | Apoptosis | ||||||
| AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital nervous system abnormality; Nervous system disease | - | Homo sapiens, Mus musculus musculus, Rattus norvegicus | 0.14 | KE:1262 | Apoptosis |
| AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic disease; Cancer | Under Development | Human and other cells in culture, Human, Mice, Rat, Canine heartworm nematode, Yeast | 0.1 | KE:112 | Antagonism, Estrogen receptor |
| AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.22 | KE:1392 | Oxidative Stress | |
| KE:1365 | Increase, Apoptosis | ||||||
| AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary system disease | - | 0.17 | KE:1392 | Oxidative Stress | |
| KE:1365 | Increase, Apoptosis | ||||||
| AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous system disease | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.29 | KE:1392 | Oxidative Stress |
| KE:352 | N/A, Neurodegeneration | ||||||
| AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | Human | 0.22 | KE:870 | Increase, Cell Proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory system disease | - | 0.18 | KE:1392 | Oxidative Stress | |
| KE:1262 | Apoptosis | ||||||
| AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | Mouse | 0.22 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous system disease | - | 0.11 | KE:1392 | Oxidative Stress | |
| KE:1825 | Increase, Cell death | ||||||
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.25 | KE:748 | Increased, Estrogen receptor (ER) activity | |
| KE:2050 | Increase, developmental abnormalities | ||||||
| AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities | |
| AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular system disease | Under Review | Human, Rat, Mouse, Rabbit | 0.25 | KE:1392 | Oxidative Stress |
| KE:2244 | Altered Stress Response Signaling | ||||||
| AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous system disease; Monogenic disease | Under Review | Human, Mouse, Rat, Rhesus monkeys, Rabbit, Guinea pig | 0.2 | KE:1392 | Oxidative Stress |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular system disease; Thoracic disease | Under Development | 0.29 | KE:1392 | Oxidative Stress | |
| KE:1532 | Decrease, Cardiac contractility | ||||||
| AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular system disease; Thoracic disease | Under Development | 0.2 | KE:1532 | Decrease, Cardiac contractility | |
| AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal system disease | Under Review | Human, Mouse, Rat, Rhesus monkeys | 0.29 | KE:1392 | Oxidative Stress |
| KE:1825 | Increase, Cell death | ||||||
| AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | Mouse | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive system disease | - | Mammals, Fish | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:496 | Androgen receptor agonism leading to reproduction dysfunction (in zebrafish) | Unclassified | - | Zebrafish | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.17 | KE:1392 | Oxidative Stress |
| AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular system disease | - | 0.29 | KE:1392 | Oxidative Stress | |
| KE:1365 | Increase, Apoptosis | ||||||
| AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.1 | KE:1392 | Oxidative Stress |
| AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | Murinae gen. sp. | 0.29 | KE:1392 | Oxidative Stress |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:549 | Aromatase inhibition leads to reproductive toxicity (including growth and developmental toxicity) in adult female zebrafish | Unclassified | - | 0.12 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |
| AOP:559 | Inhibition of acetylcholinesterase (AChE) leading to arrhythmias | Symptom | - | Human and other cells in culture, Rattus norvegicus, Dogs, Sus scrofa, Zebrafish, Insecta sp. BOLD:AAN5199 | 0.2 | KE:698 | Altered, Action Potential |
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.17 | KE:1262 | Apoptosis |
| AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | Zebrafish | 0.09 | KE:2301 | Abnormal, Behavior |
| AOP:573 | Inhibition, cytochrome oxidase leads to Increased, pulmonary edema | Respiratory system disease | - | Rodents, Humans | 0.33 | KE:1825 | Increase, Cell death |
| AOP:574 | Inhibition, cytochrome oxidase leads to Loss of olfactory function | Unclassified | - | Rodents, Humans | 0.33 | KE:1825 | Increase, Cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.25 | KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Monkey sp., Rat | 0.1 | KE:341 | Impairment, Learning and memory |
| AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental disorder of mental health | WPHA/WNT Endorsed | Rat, Mouse, Human | 0.2 | KE:1392 | Oxidative Stress |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive system disease | - | 0.2 | KE:337 | N/A, Impairment of reproductive capacity | |
| AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.08 | KE:345 | N/A, Liver Steatosis | |
| AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal system disease | Under Development | Mouse, Rat | 0.4 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.25 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | Mouse, Zebrafish, Rats, Human | 0.2 | KE:1001 | Increased, Developmental Defects |
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.22 | KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental disorder of mental health | WPHA/WNT Endorsed | Homo sapiens, Rattus sp. | 0.3 | KE:425 | Decrease of Thyroidal iodide |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:63 | Cyclooxygenase inhibition leading to reproductive dysfunction | Reproductive system disease | - | Goldfish, Human, Mouse, Rat | 0.2 | KE:675 | Reduced, Reproductive Success |
| AOP:100 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior | Reproductive system disease | - | Goldfish | 0.14 | KE:675 | Reduced, Reproductive Success |
| AOP:101 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release | Reproductive system disease | - | Goldfish | 0.14 | KE:675 | Reduced, Reproductive Success |
| AOP:102 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition | Reproductive system disease | - | Goldfish, Human, Rat, Mouse | 0.1 | KE:675 | Reduced, Reproductive Success |
| AOP:103 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint | Reproductive system disease | - | Goldfish, Human, Rat, Mouse | 0.1 | KE:675 | Reduced, Reproductive Success |
| AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal system disease | Under Review | Rattus norvegicus, Mus musculus | 0.4 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.33 | KE:768 | Increase, Cytotoxicity |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | Under Development | Mus musculus, Rattus norvegicus | 0.5 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.33 | KE:1690 | Decrease, circulating testosterone levels |
| KE:330 | Decrease, Fertility | ||||||
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.33 | KE:425 | Decrease of Thyroidal iodide |
| KE:402 | Cognitive function, decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.25 | KE:885 | Increase, Cancer |
| AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular system disease | Under Development | Human, Mouse, Rat, Cow | 0.1 | KE:952 | Hypertension |
| AOP:203 | 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline | Reproductive system disease | - | 0.12 | KE:1141 | Decreased, Reproductive Success | |
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.17 | KE:1262 | Apoptosis |
| AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal system disease | WPHA/WNT Endorsed | Rodents, Homo sapiens | 0.8 | KE:1395 | Liver Cancer |
| KE:1393 | Hepatocytotoxicity | ||||||
| KE:1392 | Oxidative Stress | ||||||
| KE:1394 | Induction, persistent proliferation/sustained proliferation | ||||||
| AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | Lemna minor, Lemna gibba | 0.09 | KE:1521 | Decrease, Growth |
| AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous system disease | - | Human | 0.29 | KE:1392 | Oxidative Stress |
| KE:1514 | Neurodegeneration | ||||||
| AOP:261 | L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility | Cardiovascular system disease | Under Development | Vertebrates | 0.25 | KE:1532 | Decrease, Cardiac contractility |
| KE:1535 | Heart failure | ||||||
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10013 | Impaired growth and development | |
| AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | 0.12 | KE:10016 | Impaired locomotor activity | |
| AOP:278 | IKK complex inhibition leading to liver injury | Unclassified | - | 0.12 | KE:1549 | Liver Injury | |
| AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous system disease | - | 0.1 | KE:352 | N/A, Neurodegeneration | |
| AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1521 | Decrease, Growth | ||||||
| AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.5 | KE:1825 | Increase, Cell death |
| KE:1521 | Decrease, Growth | ||||||
| AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine system disease | - | Human, Rat | 0.25 | KE:1616 | Malformation, cryptorchidism - maldescended testis |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | Daphnia magna | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1521 | Decrease, Growth | ||||||
| AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | Daphnia magna | 0.5 | KE:1825 | Increase, Cell death |
| KE:1521 | Decrease, Growth | ||||||
| AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | Rattus rattus, Mus musculus | 0.22 | KE:1193 | N/A, Breast Cancer |
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | 0.22 | KE:1193 | N/A, Breast Cancer | |
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive system disease | - | 0.4 | KE:1365 | Increase, Apoptosis | |
| KE:1757 | Reduce, Sperm count | ||||||
| AOP:362 | Immune mediated hepatitis | Gastrointestinal system disease; Immune system disease | - | Homo sapiens, Rat | 0.25 | KE:1820 | Immune mediated hepatitis |
| KE:1817 | Apoptotic cell death | ||||||
| AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary system disease | - | 0.33 | KE:1603 | Chronic kidney disease | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | Humans | 0.2 | KE:1868 | Hyperinflammation |
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.33 | KE:1869 | Diminished protective oxidative stress response | |
| KE:1868 | Hyperinflammation | ||||||
| AOP:430 | Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation | Viral infectious disease | Under Development | Mink, Ferret, Cat, Dog, Syrian golden hamster, Rhesus macaque, Lowland gorilla, Crab eating macaque, African green monkeys, Humans, Hippopotamus amphibius, Bank vole, Lynx canadensis, Puma concolor, Panthera tigris jacksoni, Panthera uncia, Prionailurus viverrinus, Crocuta crocuta, Arctictis binturong, Odocoileus virginianus, American mink, Nasua nasua, Panthera leo, Sus scrofa, European rabbit, Castor fiber, Aonyx cinereus, Vulpes vulpes, Nyctereutes procyonoides, Tupaia belangeri, Bos taurus, Odocoileus hemionus, Peromyscus maniculatus bairdii, Cynopterus brachyotis, Common marmoset, Baboon | 0.2 | KE:1939 | Viral infection and host-to-host transmission, proliferated |
| AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited metabolic disorder | - | Human | 0.2 | KE:1953 | Gestational diabetes mellitus |
| AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive disorder | Under Review | Rattus norvegicus, Mouse, Humans | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited metabolic disorder | - | Human | 0.5 | KE:1392 | Oxidative Stress |
| KE:2119 | Insulin resistance, increased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Mouse, Monkey, Human | 0.25 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.33 | KE:1392 | Oxidative Stress |
| KE:402 | Cognitive function, decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.25 | KE:1825 | Increase, Cell death | |
| KE:1868 | Hyperinflammation | ||||||
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental disorder of mental health | Under Development | Mouse, Rat, Human, Caenorhabditis elegans | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.38 | KE:1392 | Oxidative Stress |
| KE:2244 | Altered Stress Response Signaling | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental disorder of mental health | - | 0.18 | KE:2121 | decreased, Intellectual Quotient | |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.33 | KE:854 | Alterations, Cellular proliferation / hyperplasia | |
| KE:2135 | Prostate cancer | ||||||
| KE:1183 | Decreased, Apoptosis (Epithelial Cells) | ||||||
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:2150 | Neurological disorder |
| KE:191 | Neuronal dysfunction | ||||||
| AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.25 | KE:341 | Impairment, Learning and memory |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.57 | KE:1262 | Apoptosis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:352 | N/A, Neurodegeneration | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:1392 | Oxidative Stress |
| KE:2150 | Neurological disorder | ||||||
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.67 | KE:1065 | Activation, estrogen receptor alpha |
| KE:2251 | Estradiol availability, increased | ||||||
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.4 | KE:2204 | Altered brain morphology |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:532 | Retinoic acid receptor agonism during cerebellar development leading to impaired locomotor function | Unclassified | - | 0.2 | KE:2231 | Locomotor function. Impaired | |
| AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.17 | KE:341 | Impairment, Learning and memory | |
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.67 | KE:1392 | Oxidative Stress |
| KE:885 | Increase, Cancer | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.44 | KE:1392 | Oxidative Stress |
| KE:2233 | Decreased, ERαβ heterodimers | ||||||
| KE:1262 | Apoptosis | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular system disease | - | Fish | 0.14 | KE:1535 | Heart failure |
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular system disease | - | Human, Mouse, Rat | 0.4 | KE:2066 | Altered Signaling Pathways |
| KE:1535 | Heart failure | ||||||
| AOP:552 | Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP) | Cardiovascular system disease | - | Human, Rat, Mouse | 0.33 | KE:698 | Altered, Action Potential |
| KE:1535 | Heart failure | ||||||
| AOP:555 | Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Dogs, Rat, Guinea pig, Rabbits, Zebrafish | 0.2 | KE:1535 | Heart failure |
| AOP:556 | Decreased Na/K ATPase activity leading to heart failure | Cardiovascular system disease | - | 0.33 | KE:1532 | Decrease, Cardiac contractility | |
| KE:1535 | Heart failure | ||||||
| AOP:558 | Phosphodiesterase inhibition leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Rodents, Dog, Pig, Zebrafish | 0.33 | KE:1532 | Decrease, Cardiac contractility |
| KE:1535 | Heart failure | ||||||
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.6 | KE:2294 | Plasma estradiol, increased |
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| KE:2251 | Estradiol availability, increased | ||||||
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.33 | KE:1115 | Increase, Reactive oxygen species | |
| KE:2121 | decreased, Intellectual Quotient |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:30 | Estrogen receptor antagonism leading to reproductive dysfunction | Unclassified | Under Review | Zebra danio, Fathead minnow, Medaka | 0.17 | KE:112 | Antagonism, Estrogen receptor |
| AOP:91 | Sodium channel inhibition leading to reduced survival | Unclassified | - | Medaka, Gammarus pulex, Hydra | 0.17 | KE:584 | Inhibition, sodium channel |
| AOP:93 | sodium channel inhibition leading to increased predation | Unclassified | - | 0.25 | KE:584 | Inhibition, sodium channel | |
| AOP:94 | Sodium channel inhibition leading to congenital malformations | Unclassified | - | Human, Rat, Mouse | 0.17 | KE:584 | Inhibition, sodium channel |
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 0.43 | KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells |
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| KE:1064 | prepubertal increase, Estrogen receptor (ER) activity | ||||||
| AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | Human | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal system disease | Under Review | Homo sapiens | 0.33 | KE:1753 | Chronic reactive oxygen species |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune system disease; Musculoskeletal system disease | Under Development | Homo sapiens | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
| AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | Daphnia magna, Paracyclopina nana | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | Daphnia magna | 0.4 | KE:1365 | Increase, Apoptosis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory system disease | - | Homo sapiens | 0.25 | KE:1392 | Oxidative Stress |
| AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory system disease | - | Human | 0.17 | KE:1392 | Oxidative Stress |
| AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory system disease | - | Human | 0.17 | KE:1392 | Oxidative Stress |
| AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.17 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign neoplasm; Endocrine system disease; Reproductive system disease; Reproductive system disease; Cancer; Endocrine system disease | Under Development | Human, Rat, Mice | 0.22 | KE:1046 | Suppression, Estrogen receptor (ER) activity |
| KE:1973 | Increased, estrogens | ||||||
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | 0.25 | KE:1065 | Activation, estrogen receptor alpha | |
| KE:1987 | Decreased, Androgen and Progestin | ||||||
| AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory system disease | - | 0.15 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.18 | KE:1392 | Oxidative Stress | |
| KE:2001 | Cardiac hypertrophy | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal system disease | - | 0.15 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal system disease | - | 0.15 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:472 | DNA adduct formation leading to kidney failure | Urinary system disease | - | 0.33 | KE:1392 | Oxidative Stress | |
| KE:1825 | Increase, Cell death | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.12 | KE:1392 | Oxidative Stress |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor | |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor | |
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.44 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular system disease | - | 0.15 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.75 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
| KE:786 | Increase, Cytotoxicity (hepatocytes) | ||||||
| KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | ||||||
| AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Mouse, Rat, Lemna minor, Human, Caenorhabditis elegans | 0.75 | KE:1821 | Decrease, Cell proliferation |
| KE:1521 | Decrease, Growth | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.33 | KE:1521 | Decrease, Growth | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.6 | KE:1821 | Decrease, Cell proliferation | |
| KE:1521 | Decrease, Growth | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | Fish | 0.5 | KE:1521 | Decrease, Growth |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | Fish | 0.5 | KE:1521 | Decrease, Growth |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | Fish | 0.5 | KE:1521 | Decrease, Growth |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | Daphnia magna, Daphnia middendorffiana, Daphnia pulex, Daphnia pulicaria, Daphnia parvula | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1521 | Decrease, Growth | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation | |
| KE:1521 | Decrease, Growth | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.8 | KE:1821 | Decrease, Cell proliferation | |
| KE:1521 | Decrease, Growth | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.33 | KE:1817 | Apoptotic cell death | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | 0.36 | KE:1392 | Oxidative Stress | |
| KE:2034 | liver dysfunction | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.57 | KE:1392 | Oxidative Stress |
| KE:1869 | Diminished protective oxidative stress response | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:402 | Cognitive function, decreased | ||||||
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired metabolic disease | - | Mus musculus, Homo sapiens | 0.4 | KE:2126 | Estrogen receptor alpha inactivation |
| KE:2119 | Insulin resistance, increased | ||||||
| KE:2125 | Increased fat mass | ||||||
| KE:2129 | Metabolically unhealthy Obesity | ||||||
| AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited metabolic disorder; Disease of metabolism | - | 0.5 | KE:1392 | Oxidative Stress | |
| KE:2126 | Estrogen receptor alpha inactivation | ||||||
| KE:2119 | Insulin resistance, increased | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.6 | KE:1392 | Oxidative Stress |
| KE:885 | Increase, Cancer | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.4 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.15 | KE:2216 | Binding of antagonist to thyroid hormone receptor | |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:553 | Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure | Cardiovascular system disease | - | Human, Rodents, Dogs, Pigs, Insects, Fish | 1.0 | KE:698 | Altered, Action Potential |
| KE:1532 | Decrease, Cardiac contractility | ||||||
| KE:584 | Inhibition, sodium channel | ||||||
| KE:1535 | Heart failure |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.